Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oveporexton - Takeda

Next Previous
Drug Profile

Oveporexton - Takeda

Alternative Names: TAK-861

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Benzyl compounds; Biphenyl compounds; Fluorinated hydrocarbons; Ketones; Propanols; Pyrrolidines; Sleep disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Narcolepsy
  • No development reported Idiopathic hypersomnia

Most Recent Events

  • 14 Jul 2025 Takeda plans to submit a New Drug Application with the US FDA and additional global regulatory authorities for oveporexton in Narcolepsy, in 2025
  • 14 Jul 2025 Pooled efficacy and adverse events data from the phase III FirstLight and RadiantLight trials in Narcolepsy released by Takeda
  • 14 Jul 2025 Takeda initiates a long-term extension clinical trial in Narcolepsy (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top